LogicBio Therapeutics (LOGC) Projected to Release Quarterly Earnings on Tuesday

LogicBio Therapeutics (OTCMKTS:LOGC) is anticipated to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.0419) per share and revenue of $23.31 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:00 PM ET.

LogicBio Therapeutics (OTCMKTS:LOGC) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $33.60 million for the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Trading Up 0.3%

Shares of OTCMKTS:LOGC opened at $15.30 on Tuesday. LogicBio Therapeutics has a 12-month low of $7.05 and a 12-month high of $15.41. The business has a 50 day moving average of $14.03 and a 200-day moving average of $9.96. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.

LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.